Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer
Ligand Reports Second Quarter 2015 Financial Results
Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844
Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
Ligand to Report Second Quarter Results on August 4th
Ligand to Participate in Four Upcoming Investor Conferences
FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial
Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions
Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance
Ligand Reports First Quarter 2015 Financial Results
Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
